[go: up one dir, main page]

DE60237158D1 - Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen - Google Patents

Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
DE60237158D1
DE60237158D1 DE60237158T DE60237158T DE60237158D1 DE 60237158 D1 DE60237158 D1 DE 60237158D1 DE 60237158 T DE60237158 T DE 60237158T DE 60237158 T DE60237158 T DE 60237158T DE 60237158 D1 DE60237158 D1 DE 60237158D1
Authority
DE
Germany
Prior art keywords
compositions
treatment
subjects
methods
neurodeegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237158T
Other languages
English (en)
Inventor
Keiya Ozawa
Shin-Ichi Muramatsu
Kunihiko Ikeguchi
Imaharu Nakamo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23226283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60237158(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DE60237158D1 publication Critical patent/DE60237158D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60237158T 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen Expired - Lifetime DE60237158D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31583801P 2001-08-29 2001-08-29
PCT/JP2002/008761 WO2003018821A2 (en) 2001-08-29 2002-08-29 Compositions and methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DE60237158D1 true DE60237158D1 (de) 2010-09-09

Family

ID=23226283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237158T Expired - Lifetime DE60237158D1 (de) 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Country Status (10)

Country Link
US (1) US20030050273A1 (de)
EP (1) EP1421199B1 (de)
JP (1) JP4279141B2 (de)
KR (1) KR20040039316A (de)
CN (1) CN1304581C (de)
AT (1) ATE475716T1 (de)
AU (1) AU2002326163B2 (de)
CA (1) CA2457057C (de)
DE (1) DE60237158D1 (de)
WO (1) WO2003018821A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
AU2002359786A1 (en) * 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
EP1478236B1 (de) * 2001-12-21 2009-02-11 The Salk Institute For Biological Studies Zielgerichtete retrograde genabgabe an motoneuronen
EP1660659A2 (de) * 2003-09-05 2006-05-31 Licentia, Ltd. Mit gdnf verwandte neuropeptide
ATE460183T1 (de) 2003-10-20 2010-03-15 Nsgene As Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson
WO2005074605A2 (en) * 2004-02-03 2005-08-18 University Of Rochester Recombinant molecular products for expression of heme oxygenase-1, heme oxygenase-2, and/or biliverdin reductase for treatment of neurodegenerative diseases or disorders
JP4779120B2 (ja) 2004-07-02 2011-09-28 国立大学法人大阪大学 内視鏡アタッチメントおよび内視鏡
CA2606490C (en) 2005-05-02 2018-02-06 Genzyme Corporation Gene therapy for spinal cord disorders
EP3058959B1 (de) * 2005-05-02 2019-01-30 Genzyme Corporation Gentherapie für neurometabolische erkrankungen
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
CA2751266A1 (en) 2009-01-29 2010-08-05 Krystof Bankiewicz Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
ES2903127T3 (es) * 2009-05-02 2022-03-31 Genzyme Corp Terapia génica para trastornos neurodegenerativos
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CN103189507A (zh) * 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
CN102618507B (zh) * 2012-03-23 2015-04-22 首都医科大学 增加腺相关病毒靶向转导效率的重组腺相关病毒及其应用
US8999927B2 (en) 2012-04-02 2015-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
JP7023108B2 (ja) 2014-10-21 2022-02-21 ユニバーシティ オブ マサチューセッツ 組み換えａａｖバリアントおよびその使用
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
EP3569708A4 (de) 2017-01-13 2020-09-09 Jichi Medical University Aav-vektor zur unterbrechung des mit der gerinnung zusammenhängenden faktorgens auf dem lebergenom
US12064460B2 (en) 2018-01-26 2024-08-20 Tokushima University Adeno-associated virus virion for treatment of Tay-Sachs disease and Sandhoff disease
CN110499330A (zh) * 2018-05-16 2019-11-26 上海市同济医院 重组腺相关病毒载体及其应用
US12188040B2 (en) 2018-07-30 2025-01-07 Gene Therapy Research Institution Co., Ltd. Method for enhancing gene expression using AAV vector
WO2020093035A1 (en) 2018-11-02 2020-05-07 The Johns Hopkins University Adenoviral chimeric tdp-43 proteins
US20220265853A1 (en) 2019-07-12 2022-08-25 Gene Therapy Research Institution Co., Ltd. Adeno-associated virus virion for gene transfer to human liver
EP4328313A1 (de) 2021-04-21 2024-02-28 Jichi Medical University Adeno-assoziiertes virus-virion zur behandlung von ornithintranscarbamylasemangel
AU2022397707A1 (en) * 2021-11-29 2024-06-13 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
WO1993006116A1 (en) * 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
AU7676894A (en) * 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
CA2187626C (en) * 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
EP1612272B1 (de) * 1996-05-03 2011-06-22 Abbott Laboratories Antiangiogenische Polypeptide und Verfahren zur Angiogenesehemmung
DE69929600T2 (de) * 1998-05-27 2006-09-07 Avigen Inc., Alameda Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
CN1228995A (zh) * 1999-01-26 1999-09-22 卢杲 一种治疗老年性痴呆症、帕金森症、心脑血管病的药物
US6800281B2 (en) * 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases

Also Published As

Publication number Publication date
CA2457057C (en) 2011-05-10
CN1304581C (zh) 2007-03-14
EP1421199B1 (de) 2010-07-28
EP1421199A2 (de) 2004-05-26
KR20040039316A (ko) 2004-05-10
CA2457057A1 (en) 2003-03-06
JP4279141B2 (ja) 2009-06-17
ATE475716T1 (de) 2010-08-15
WO2003018821A3 (en) 2003-10-30
CN1575340A (zh) 2005-02-02
JP2005501127A (ja) 2005-01-13
WO2003018821A2 (en) 2003-03-06
US20030050273A1 (en) 2003-03-13
AU2002326163B2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
DE60237158D1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DK0822829T3 (da) Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
EA200901299A1 (ru) Композиции олигогулуроната и олигогалактуроната
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
BR112014016557A8 (pt) métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
HRP20010877B1 (en) Composition for prevention and treatment of amyloidogenic disease
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
ATE407690T1 (de) Topische pharmazeutische zusammensetzungen enthaltend aktive natürliche bestandteile zur verhütung und behandlung von mucosalen entzündungprozessen
WO2007035722A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DE69819488D1 (de) Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
DK1082131T3 (da) Immunoregulator
WO2007134118A3 (en) Protein based composition and methods of using same
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
ATE546159T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff
DE60129606D1 (de) Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
WO2008043570A8 (en) Interferon type i supporting compounds
BR9908518A (pt) Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios